Results 181 to 190 of about 346,103 (330)

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future

American Journal of Hematology, EarlyView.
ABSTRACT With the recent publication of new classification systems of hematopoietic neoplasms, understanding how recognition of disease entities has occurred over time and the subsequent development of formal disease classifications is of importance. This review focuses on the early recognition of myeloid disorders, especially chronic myeloid disorders,
Daniel A. Arber, Attilio Orazi
wiley   +1 more source

A cytotoxic survey on 2‐amino‐1H‐imidazol based synthetic marine sponge alkaloid analogues

Drug Development Research, Volume 83, Issue 8, Page 1906-1922, December 2022., 2022
Abstract Here, we describe the synthesis and biologic activity evaluation of 20 novel synthetic marine sponge alkaloid analogues with 2‐amino‐1H‐imidazol (2‐AI) core. Cytotoxicity was tested on murine 4T1 breast cancer, A549 human lung cancer, and HL‐60 human myeloid leukemia cells by the resazurin assay.
Nikolett Gémes, Zsófia Makra, Patrícia Neuperger, Enikő Szabó, József Á. Balog, Lili Borbála Flink, Beáta Kari, László Hackler Jr, László. G. Puskás, Iván Kanizsai, Gábor J. Szebeni   +10 more
wiley   +1 more source

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

American Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley   +1 more source

Flt3L, LIF, and IL‐10 combination promotes the selective in vitro development of ESAMlow cDC2B from murine bone marrow

European Journal of Immunology, Volume 52, Issue 12, Page 1946-1960, December 2022., 2022
In vitro culture of murine bone marrow cells in Flt3L + LIF + IL‐10 promotes CD11b+ ESAMlow cDC2B subset generation from CDP but blocks cDC1 and pDC development. Flt3L alone or combined does not induce cDC2A generation in vitro. Abstract The development of two conventional dendritic cells (DC) subsets (cDC1 and cDC2) and the plasmacytoid DC (pDC) in ...
Laura Cyran, Julia Serfling, Luisa Kirschner, Hartmann Raifer, Michael Lohoff, Heike M. Hermanns, Andreas Kerstan, Jochen Bodem, Manfred B. Lutz   +8 more
wiley   +1 more source

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma

Oman Journal of Ophthalmology, 2021
Carol L. Shields, Ann-Marie Leahey
openaire   +4 more sources

Topics of Interest in Women With Myeloproliferative Neoplasms

American Journal of Hematology, EarlyView.
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber, Paola Guglielmelli, Naseema Gangat   +2 more
wiley   +1 more source

The thioredoxin system: Balancing redox responses in immune cells and tumors

European Journal of Immunology, Volume 53, Issue 1, January 2023., 2023
The thioredoxin (TRX) system is a critical contributor to cellular redox homeostasis in all living cells. Here, we review the key roles of TRX for activation, proliferation, and responses in T cells, B cells, and myeloid cells. Further, we conceptualize how this knowledge may be therapeutically exploited for cancer treatment.
Jonathan Muri, Manfred Kopf
wiley   +1 more source

A Phase II Trial of Geriatric Assessment‐Guided Selection of Treatment Intensity in Older Adults With AML

American Journal of Hematology, EarlyView.
ABSTRACT How to select the appropriate intensity of chemotherapy in older adults with acute myeloid leukemia (AML) remains an unanswered question. In a phase II trial of older adults ≥ 60 years with AML (n = 73), we used geriatric assessment (measures of comorbidity burden, physical and cognitive function) to determine fitness for intensive ...
Vijaya R. Bhatt, Christopher S. Wichman, Thuy T. Koll, Alfred L. Fisher, Tanya M. Wildes, Michael Haddadin, Ann M. Berger, James O. Armitage, Sarah A. Holstein, Lori J. Maness, Krishna Gundabolu   +10 more
wiley   +1 more source